Abstract
The nutritional compound capsaicin is the major spicy ingredient of chili peppers. Although traditionally associated with analgesic activity, recent studies have shown that capsaicin has profound antineoplastic effects in several types of human cancers. However, the applications of capsaicin as a clinically viable drug are limited by its unpleasant side effects, such as gastric irritation, stomach cramps, and burning sensation. This has led to extensive research focused on the identification and rational design of second-generation capsaicin analogs, which possess greater bioactivity than capsaicin. A majority of these natural capsaicinoids and synthetic capsaicin analogs have been studied for their pain-relieving activity. Only a few of these capsaicin analogs have been investigated for their anticancer activity in cell culture and animal models. The present review summarizes the current knowledge of the growth-inhibitory activity of natural capsaicinoids and synthetic capsaicin analogs. Future studies that examine the anticancer activity of a greater number of capsaicin analogs represent novel strategies in the treatment of human cancers.
Footnotes
- Received June 30, 2017.
- Accepted December 13, 2017.
↵1 J.R.F., N.A.N., and K.C.B. contributed equally to this work as first authors.
This work was supported by the MU-WVU Health Partnership award and National Institutes of Health R15 Academic Research Enhancement Award (Grants 1R15CA161491-01A1 and 2R15CA161491-02 to P.D.). A.T.A. and N.A.N. were recipients of a National Aeronautics and Space Administration undergraduate research fellowship from the West Virginia space grant consortium. A.T.A. is also a recipient of the National Science Foundation-Summer Undergraduate Research in Engineering summer research fellowship. This work was supported in part by the West Virginia Institutional Development Award Network of Biomedical Research Excellence grant (National Institutes of Health Grant P20GM103434; PI: Dr. G. Rankin), Institutional Development Award, National Institutes of Health National Institute of General Medical Sciences [Grant P20GM104932], and Research Core B of Centers of Biomedical Research Excellence, a component of the National Institutes of Health.
The authors have no financial disclosure or conflict of interest.
- Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|